Andrew Meds review

There is a genuine low-dose lane here and you would never find it by reading the site. Every start button on the compounded semaglutide page opens a separate intake headed with a microdosing program, offering one product at a third under the price the page you came from advertises — and the word microdosing does not appear on the public site in any spelling. A second intake, reached from the tirzepatide page, offers no tirzepatide at all and prices a four-week semaglutide supply at a third figure, on a savings ladder whose own arithmetic does not reconcile. So three semaglutide prices are live at once and nothing on the site connects them. What is better than average is the coverage disclosure: forty-four states are named as questionnaire care and seven jurisdictions are named as requiring a live consultation first, both printed in full rather than summarized as nationwide. The prescribing practice is named in every footer with its own address and phone number. No milligram is published against any of the three prices, so the low-dose figure cannot be tied to an amount.

Vs median

$27/mo above the $172 median across the 254 of 393 programs we track that publish a plain monthly rate

Market

$59–$1300/mo is the full published spread in our ranking

Structure

Charges less for less

Consult

Included in the price

Dietitian

Not included

Labs

Not required

Pricing

Varies by dose, plan or tier

Price last updated

September 2026

Andrew Meds dispenses through a 503(A) pharmacy or 503(B) outsourcing facility — neither named facility. No bloodwork is required before you start. A clinician review is included in the price.

Andrew Meds publishes clean month-to-month rates for compounded semaglutide and compounded tirzepatide with a prepay ladder beside each, and it is unusually specific about how it delivers care by state: forty-four states get asynchronous questionnaire care, seven jurisdictions require a live consultation first, and both lists are printed in full. Underneath that tidy surface the pricing is not settled. Clicking through from the semaglutide page lands a reader in an intake titled Microdosing Program that offers one product, Semaglutide Microdosing, at $99 a month — a low-dose lane at a third off, and one the public site never mentions in any spelling. A different intake, reached from the tirzepatide page, offers no tirzepatide at all and prices a four-week semaglutide supply at $149 on a ladder whose own savings arithmetic does not reconcile. Prescribing is attributed to Dr Tel X, an independent practice named in every footer with its own address and phone number, though no individual clinician and no compounding pharmacy is named; the product pages disclose only that a prescription is prepared by a 503(A) pharmacy or a 503(B) outsourcing facility.

THREE SEMAGLUTIDE PRICES ARE LIVE AT ONCE — $199 a month on the product page, $99 a month in the microdosing intake, and $149 for a four-week supply in a third — and nothing reconciles them

• The microdosing program is invisible on the public site: the word does not appear on it in any spelling, so a reader only meets the $99 lane by clicking through
• The tirzepatide intake offers no tirzepatide — the only treatment on its first screen is semaglutide injections
• NO MILLIGRAM IS PUBLISHED against any figure, including the microdosing one
• The intake carries a live scarcity countdown, unsourced outcome statistics and a review badge that corresponds to no profile, none of which appears on the public site
• A money-back guarantee is promised inside the intake while the terms say there are no refunds for partially used periods
• The District of Columbia is claimed as served and named among the live-visit jurisdictions, but cannot be selected in the intake
• No pharmacy is named, and prescriptions may be transferred between unnamed pharmacies without notice
• Compounded GLP-1s are not FDA-approved, and intentional microdosing is off-label and unproven

Andrew Meds is one of 393 low-dose GLP-1 programs we track, and 254 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What the evidence actually shows
• What microdosing GLP-1 costs
• Microdosing semaglutide
• The true annual cost of a plan
• What a flat price costs at a low dose